Related Experiment Videos
New treatment approaches for metastatic renal cell carcinoma
1Division of Hematology and Medical Oncology, Departments of Medicine and Urology, Joan and Sanford I. Weill Medical College of Cornell University, 525 East 68th Street, B-1519, New York, NY 10021, USA. dnanus@mail.med.cornell.edu
Abstract:
Metastatic renal cell carcinoma remains a disease that is highly resistant to systemic therapy and difficult to treat. Numerous studies with many different treatment modalities have resulted in only minor advances. No single agent or combination therapy has consistently shown a response proportion of 20% or higher. Interleukin-2 and interferon-alpha-based therapies are most commonly used to treat advanced disease, demonstrating low but reproducible response proportions in the 10% to 20% range, with durable responses of 5% or less. In the last few years, randomized studies have for the first time demonstrated a survival advantage for patients receiving systemic therapy, although this advantage is marginal. A number of novel treatment strategies are being investigated with some encouraging early results. The identification of new agents with better antitumor activity remains a high priority in the treatment of advanced renal cell carcinoma.
Insights
Metastatic renal cell carcinoma is difficult to treat, with limited treatment options showing modest results. New agents with improved antitumor activity are urgently needed for advanced kidney cancer.
Area of Science:
- Oncology
- Nephrology
- Translational Medicine
Background:
- Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges due to high resistance to systemic therapies.
- Current treatments, including Interleukin-2 and interferon-alpha, offer limited response rates (10-20%) and minimal durable responses (<5%).
Purpose of the Study:
- To review the current landscape of metastatic renal cell carcinoma treatment.
- To highlight the unmet need for effective systemic therapies in advanced kidney cancer.
- To discuss emerging novel treatment strategies and the priority for new agents with enhanced antitumor activity.
Main Methods:
- Review of existing literature and clinical studies on metastatic renal cell carcinoma treatment modalities.
- Analysis of response proportions and survival advantages from various systemic therapies.
- Examination of ongoing investigations into novel treatment strategies.
Main Results:
- No single agent or combination therapy has consistently achieved response proportions of 20% or higher.
- Recent randomized studies show a marginal survival advantage for systemic therapy in advanced disease.
- Early results from novel treatment strategies are encouraging, indicating potential progress.
Conclusions:
- Metastatic renal cell carcinoma remains a highly resistant malignancy requiring more effective treatments.
- The development of new agents with superior antitumor activity is a critical priority for improving outcomes in advanced kidney cancer.
- Ongoing research into novel strategies offers hope for future therapeutic advancements.